Clinical trials of Russian anti-coronavirus COVID-19 is scheduled to be completed in 4-8 weeks. This was told the chief urologist of Ministry of health of Russian Federation, academician Dmitry Pushkar. He is responsible for the implementation of the Protocol studies of the drug in Russia.
the fact that Russia has successfully produced the first and most powerful at this point drug for the treatment COVID-19, it was reported yesterday. Local laboratories were able to establish production process in just two months, and sent to hospital experienced party has already proven its effectiveness.
Clinical trials will be conducted on several hundred patients — in particular, in Moscow and St. Petersburg, as well as in Mordovia, which produces the drug. Upon completion of the clinical trial documents will be filed for registration of the drug, Pushkar told RIA Novosti. In a press-service of the Russian health Ministry earlier announced that the deadline to market this drug from COVID-19 will be reduced.
In the first phase, the drug “Favipiravir” under the trade name “Replevin” to be used only for the treatment of patients with moderate severity of the disease. For heavy patients on a ventilator, “Replevin” while will not be used, said Pushkar: studies for its application and severe patients will hold later.
“Absolutely, that medicine will appear before the vaccine, but you need to work in the other direction,” — said the academician.
treatment of patients with COVID-19 drug “Replevin”, he said, has already been developed: an average treatment will take no more than a week. Preclinical trials in animal models have shown that it acts on the virus, destroying it in 5-6 days.
